Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02365714
Other study ID # CRC012015-02
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received February 11, 2015
Last updated March 16, 2018
Start date February 2015
Est. completion date January 2017

Study information

Verified date June 2016
Source Georgetown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects and cosmetic results.


Description:

This study will determine the feasibility, acute and late toxicity as well as oncologic outcomes following CK-SAPBI.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 99 Years
Eligibility Inclusion Criteria:

- -Newly diagnosed Stage 0 or I breast cancer.

- On histological examination, the tumor must be DCIS or invasive non-lobular carcinoma of the breast

- Surgical treatment of the breast must have been wide excision, lumpectomy or partial mastectomy

- Age 50 years or greater

- ER positive: (=1% of breast tumor cells express ER in their nuclei)

- PR (progesterone receptor) positive: (= 1% of breast tumor cells express PR in their nuclei)

- Her2 negative (IHC 0-1+; for IHC 2+, FISH (fluorescence in situ hybridization) must be non-amplified)

- Subjects with invasive tumors should undergo axillary sentinel lymph node evaluation or axillary lymph node dissection.

- Negative inked surgical margins of excision or re-excision, clear of invasive tumor (no cells on ink) and DCIS by at least 1 mm

- Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications with no remaining suspicious calcifications in the breast before radiotherapy. Alternatively, a specimen radiograph can be obtained showing all the suspicious calcifications.

- No involved axillary lymph nodes, N0(i+) allowed

- Enrollment and the plan to initiate of CyberKnife therapy within 12 weeks of the last breast cancer surgery.

- Target lumpectomy cavity/whole breast reference volume must be <30% based on treatment planning CT

- Signed study-specific informed consent form

Exclusion Criteria:

- -Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.

- Patients with tumors greater than 2 cm

- Patients with surgical margins which cannot be microscopically assessed or not cleared by at least 2mm at pathological evaluation.

- Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy. Breast MRI will be recommended to exclude multicentric disease and additional suspicious areas will require biopsy to exclude malignancy.

- Patient with lymphovascular space invasion (LVSI).

- Patients with involved axillary nodes.

- Patients with collagen vascular diseases.

- Patient with known deleterious BRCA1/2 mutations or known mutations in other high penetrance genes (TP53, STK11, PTEN-phosphatase and tensin homolog, CDH1)

- Patients with prior ipsilateral breast irradiation.

- Patients with prior ipsilateral thoracic irradiation.

- Patients with Paget's disease of the nipple.

- Patients with diffuse suspicious microcalcifications.

- Patients with suspicious microcalcifications remaining on the post-excision mammogram.

- Patients receiving (neo)adjuvant systemic therapy other than hormonal therapy

- Patients with oncoplastic reconstruction and absence of surgical clips

Study Design


Intervention

Radiation:
CK Stereotactic Accelerated Partial Breast Irradiation
Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.

Locations

Country Name City State
United States Georgetown University Hospital Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Georgetown University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Primary Endpoint for This Study is the Percentage of Enrolled Subjects in Whom CyberKnife SAPBI PBI is Technically Feasible to Deliver and Complete Treatment Only one of two patients were able to undergo CyberKnife SAPBI. We are measuring the percentage of enrolled subjects in whom CyberKnife SAPBI PBI is technically feasible to deliver and complete treatment Enrollment to 24 months
Primary Feasibility How many patients were able to undergo CK SAPBI 2 years
Secondary Ipsilateral Breast Recurrence No patients have recurred to date. 1 month post radiation treatment through 5 years post treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2